Genetic polymorphisms of ADRB2 have been reported to modulate the functional responses of the receptor to adrenergic stimulation (Dhein et al., 2017), which may be associated with cardiovascular events and all-cause mortality in CAD patients. This evidence concerns the gene ADRB2 and coronary artery disorder.